Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms.

Sørlie T, Wang Y, Xiao C, Johnsen H, Naume B, Samaha RR, Børresen-Dale AL.

BMC Genomics. 2006 May 26;7:127.

2.

[Molecular classification of breast cancer].

Zepeda-Castilla EJ, Recinos-Money E, Cuéllar-Hubbe M, Robles-Vidal CD, Maafs-Molina E.

Cir Cir. 2008 Jan-Feb;76(1):87-93. Review. Spanish.

PMID:
18492427
3.

Genomic instability in breast cancer: pathogenesis and clinical implications.

Kwei KA, Kung Y, Salari K, Holcomb IN, Pollack JR.

Mol Oncol. 2010 Jun;4(3):255-66. doi: 10.1016/j.molonc.2010.04.001. Epub 2010 Apr 9. Review.

4.
5.

Luminal-B breast cancer and novel therapeutic targets.

Tran B, Bedard PL.

Breast Cancer Res. 2011;13(6):221. doi: 10.1186/bcr2904. Epub 2011 Nov 30. Review.

6.
7.

Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction.

Colombo PE, Milanezi F, Weigelt B, Reis-Filho JS.

Breast Cancer Res. 2011 Jun 27;13(3):212. doi: 10.1186/bcr2890. Review.

8.

Interpretation of microarray data in cancer.

Michiels S, Koscielny S, Hill C.

Br J Cancer. 2007 Apr 23;96(8):1155-8. Epub 2007 Mar 6. Review.

9.

Metastatic Organotropism: An Intrinsic Property of Breast Cancer Molecular Subtypes.

Wei S, Siegal GP.

Adv Anat Pathol. 2017 Mar;24(2):78-81. doi: 10.1097/PAP.0000000000000140. Review.

PMID:
28098572
10.

Signatures of tumor-immune interactions as biomarkers for breast cancer prognosis.

Manjili MH, Najarian K, Wang XY.

Future Oncol. 2012 Jun;8(6):703-11. doi: 10.2217/fon.12.57. Review.

11.

Expression profiling of small cellular samples in cancer: less is more.

Glanzer JG, Eberwine JH.

Br J Cancer. 2004 Mar 22;90(6):1111-4. Review.

12.

Recent candidate molecular markers: vitamin D signaling and apoptosis specific regulator of p53 (ASPP) in breast cancer.

Patel JB, Patel KD, Patel SR, Shah FD, Shukla SN, Patel PS.

Asian Pac J Cancer Prev. 2012;13(5):1727-35. Review.

13.

Role of IGF1R in Breast Cancer Subtypes, Stemness, and Lineage Differentiation.

Farabaugh SM, Boone DN, Lee AV.

Front Endocrinol (Lausanne). 2015 Apr 24;6:59. doi: 10.3389/fendo.2015.00059. eCollection 2015. Review.

14.

Gene-expression profiling in rheumatic disease: tools and therapeutic potential.

Bauer JW, Bilgic H, Baechler EC.

Nat Rev Rheumatol. 2009 May;5(5):257-65. doi: 10.1038/nrrheum.2009.50. Review.

PMID:
19412192
15.

Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset.

Choi W, Ochoa A, McConkey DJ, Aine M, Höglund M, Kim WY, Real FX, Kiltie AE, Milsom I, Dyrskjøt L, Lerner SP.

Eur Urol. 2017 Mar 29. pii: S0302-2838(17)30175-6. doi: 10.1016/j.eururo.2017.03.010. [Epub ahead of print] Review.

PMID:
28365159
16.

Genomic approaches in breast cancer research.

Donahue HJ, Genetos DC.

Brief Funct Genomics. 2013 Sep;12(5):391-6. doi: 10.1093/bfgp/elt019. Epub 2013 Jun 20. Review.

17.

Fatty acid metabolism in breast cancer subtypes.

Monaco ME.

Oncotarget. 2017 Apr 25;8(17):29487-29500. doi: 10.18632/oncotarget.15494. Review.

18.

Breast cancer intrinsic subtype classification, clinical use and future trends.

Dai X, Li T, Bai Z, Yang Y, Liu X, Zhan J, Shi B.

Am J Cancer Res. 2015 Sep 15;5(10):2929-43. eCollection 2015. Review.

19.

Histological and molecular types of breast cancer: is there a unifying taxonomy?

Weigelt B, Reis-Filho JS.

Nat Rev Clin Oncol. 2009 Dec;6(12):718-30. doi: 10.1038/nrclinonc.2009.166. Review.

PMID:
19942925
20.

Overview of Genetically Engineered Mouse Models of Distinct Breast Cancer Subtypes.

Usary J, Darr DB, Pfefferle AD, Perou CM.

Curr Protoc Pharmacol. 2016 Mar 18;72:14.38.1-11. doi: 10.1002/0471141755.ph1438s72. Review.

Supplemental Content

Support Center